Genzyme Corp.
- Address
- 450 Water Street
Sponsor Overview
Specializations
Gaucher disease and lysosomal storage disorders
Research activity includes Gaucher disease type 1 and Gaucher disease type 3, with attention to both systemic disease control and central nervous system involvement. The portfolio reflects interest in substrate reduction therapy, enzyme replacement therapy, and biomarker-based assessment in adult and pediatric populations.
- Eliglustat
- Imiglucerase
- Venglustat
Clinical interest extends to cerebrospinal fluid biomarkers, neurologic manifestations of Gaucher disease type 3, and treatment approaches spanning combination therapy and maintenance therapy.
Hemophilia and bleeding disorders
The sponsor supports studies in hemophilia A and hemophilia B, including patients with and without inhibitory antibodies. The research focus centers on preventive treatment strategies and safety evaluation in both adult and pediatric populations.
- Fitusiran
- Factor VIII and factor IX deficiency
- Hemostatic prophylaxis
Areas of interest include long-term tolerability, treatment optimization in young children, and management of severe bleeding risk across inherited coagulation disorders.
Pediatric hematology and rare disease treatment
Several trials address treatment use in children and adolescents with rare inherited disorders, with emphasis on age-specific safety, pharmacokinetics, and clinical monitoring. This includes pediatric patients with Gaucher disease and hemophilia.
- Pediatric pharmacokinetics
- Long-term safety
- Rare genetic disorders
The sponsor’s portfolio shows sustained interest in therapies suited to younger patients, including conditions requiring chronic management and careful evaluation of tolerability.
Primary progressive multiple sclerosis
Research also includes primary progressive multiple sclerosis, with a focus on slowing disability progression and addressing neuroinflammatory disease mechanisms. The therapeutic area reflects interest in neurology and progressive demyelinating disease.
- Bruton’s tyrosine kinase inhibition
- Tolebrutinib (SAR442168)
- Disability progression
The trial portfolio includes evaluation of treatments targeting progressive neurologic impairment in a chronic autoimmune condition.
Sponsored Trials
Data & Insights
This sponsor works with 8 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 114 sites across their trial portfolio.
Therapeutic Focus
- 1.Congenital, Hereditary, and Neonatal Diseases and Abnormalities2 trials165 other sponsors
- 2.Hemic and Lymphatic Diseases2 trials249 other sponsors
- 3.Nervous System Diseases1 trial449 other sponsors
Partnered Research Centres
114 centres- Address
- Panagioti Kanellopoulou Av 1, 115 25 Athens
- Address
- Bulevard Nikola Yonkov Vaptsarov 51b, 1407 Sofia
- Address
- Molengracht 21, 4818 CK Breda
- Address
- Pylea, Asklipiou 10, 546 39 Thessaloniki
- Address
- Via Nicolo' Giustiniani 2, 35128 Padua
- Address
- Via Sergio Pansini 5, 80131 Naples
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Genzyme Corp..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.